Genmab A (GMAB) EPS (Basic) (2018 - 2026)
Genmab A's (GMAB) quarterly EPS (Basic) came in at $4.43 in Q2 2026, down 63.48% on a YoY basis from $12.14 in Q2 2025, and down 94.95% quarter-over-quarter from $87.79 in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) EPS (Basic) (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported EPS (Basic) for 9 consecutive years, with $4.43 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 63.48% year-over-year to $4.43; the trailing twelve-month figure through Jun 2026 stood at $193.49 (up 36.68% YoY), and the FY2025 full-year result was $14.88, down 27.02% from the prior year.
- EPS (Basic) declined to $4.43 in Q2 2026 per GMAB's latest filing, from $87.79 in the prior quarter.
- Across five years, EPS (Basic) topped out at $87.79 in Q1 2026 and bottomed at -$38.44 in Q4 2023.
- Historically, EPS (Basic) has averaged $30.94 across 5 years, with a median of $40.12 in 2022.
- The sharpest annual moves came in 2023 and 2025: EPS (Basic) plunged 3416.74% in 2023, then surged 302.57% in 2025.
- Over 5 years, EPS (Basic) stood at $1.16 in 2022, then tumbled by 3416.74% to -$38.44 in 2023, then soared by 220.75% to $46.42 in 2024, then surged by 87.33% to $86.95 in 2025, then sank by 94.9% to $4.43 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered $4.43, $87.79, and $86.95 for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.62 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -1.96 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 7.70 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -0.40 |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 4.43 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.43 |
| Mar 31, 2026 | 87.79 |
| Sep 30, 2025 | 86.95 |
| Jun 30, 2025 | 12.14 |
| Mar 31, 2025 | 80.07 |
| Sep 30, 2024 | 46.42 |
| Jun 30, 2024 | 3.02 |
| Mar 31, 2024 | 47.44 |
| Dec 31, 2023 | -38.44 |
| Sep 30, 2023 | 45.38 |
| Jun 30, 2023 | 2.55 |
| Mar 31, 2023 | 41.03 |
| Dec 31, 2022 | 1.16 |
| Sep 30, 2022 | 40.12 |
| Jun 30, 2022 | 4.02 |
| Dec 31, 2021 | -35.97 |
| Sep 30, 2021 | 39.02 |
| Jun 30, 2021 | 2.68 |
| Mar 31, 2021 | 22.56 |
| Dec 31, 2020 | 26.50 |